Heimesaat Markus M, Mousavi Soraya, Weschka Dennis, Bereswill Stefan
Gastrointestinal Microbiology Research Group, Institute of Microbiology, Infectious Diseases and Immunology, Charité-University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 12203 Berlin, Germany.
Microorganisms. 2021 Jan 14;9(1):169. doi: 10.3390/microorganisms9010169.
Human infections with enteropathogenic () including multi-drug resistant isolates are emerging worldwide. Antibiotics-independent approaches in the combat of campylobacteriosis are therefore highly desirable. Since the health-beneficial including anti-inflammatory and anti-infectious properties of cardamom have been acknowledged for long, we here addressed potential anti-pathogenic and immune-modulatory effects of this natural compound during acute campylobacteriosis. For this purpose, microbiota-depleted IL-10 mice were orally infected with strain 81-176 and subjected to cardamom essential oil (EO) via the drinking water starting on day 2 post-infection. Cardamom EO treatment resulted in lower intestinal pathogen loads and improved clinical outcome of mice as early as day 3 post-infection. Furthermore, when compared to mock controls, cardamom EO treated mice displayed less distinct macroscopic and microscopic inflammatory sequelae on day 6 post-infection that were paralleled by lower colonic numbers of macrophages, monocytes, and T cells and diminished pro-inflammatory mediator secretion not only in the intestinal tract, but also in extra-intestinal and, remarkably, systemic organs. In conclusion, our preclinical intervention study provides the first evidence that cardamom EO comprises a promising compound for the combat of acute campylobacteriosis and presumably prevention of post-infectious morbidities.
包括多重耐药菌株在内的人类肠道致病性弯曲杆菌感染正在全球范围内出现。因此，在对抗弯曲杆菌病方面，不依赖抗生素的方法非常可取。由于小豆蔻的有益健康特性（包括抗炎和抗感染特性）早已得到认可，我们在此研究了这种天然化合物在急性弯曲杆菌病期间的潜在抗病原和免疫调节作用。为此，将微生物群耗尽的IL-10小鼠经口感染81-176菌株，并在感染后第2天开始通过饮用水给予小豆蔻精油（EO）。小豆蔻EO治疗早在感染后第3天就降低了肠道病原体载量，并改善了小鼠的临床结局。此外，与模拟对照组相比，小豆蔻EO处理的小鼠在感染后第6天表现出不太明显的宏观和微观炎症后遗症，同时结肠中巨噬细胞、单核细胞和T细胞数量减少，不仅肠道内，而且肠道外及全身器官中的促炎介质分泌也减少。总之，我们的临床前干预研究首次证明，小豆蔻EO是对抗急性弯曲杆菌病和预防感染后发病的一种有前景的化合物。
